The news is by your side.


In diabetes war, Novo Nordisk aims to break mold with new pill

LONDON: After nearly a century building a company worth $125 billion based on injectable drugs, Denmark’s Novo Nordisk - the world’s biggest insulin maker - wants to prove this year it can transform the diabetes market with a pill. Novo’s oral semaglutide medicine is important for ensuring the group’s long-term growth - a critical mission after 2017 results last week revealed mounting price pressure in a crowded market targeting the world’s 450 million diabetics. Rivals, especially Eli Lilly, are watching Novo’s…